← boardnext 2027-12
AKTS
Aktis Oncology, Inc.distress 1/10 · well-funded / low risk$23.86-4%today-26% from 52w high
Lead: Urothelial Carcinoma Bladder
Revenue
pre-revenue
Liquidity
$372M
Runway
3.8 yrs
Shares 1y
—
Price & events
+6.5% over 6M
CatalystRating changeDilutionFinancingdashed = today
-3.8%
1D
-4.6%
1W
-11.7%
1M
+8.1%
3M
+10.2%
6M
—
1Y
—
2Y
—
5Y
+6.5%
All
Overview
- Volume
- 15.64K
- 52 Week Range
- $15.19 – $32.23
- Float Shares
- 28.15M
- Short %
- 20.90%
- % Held by Insiders
- 14.14%
- % Held by Institutions
- 74.28%
- RVOL
- 0.03x
Pipeline stages · 1 programs
[225Ac]Ac-AKY-1189 (therapeutic), [64Cu]Cu-AKY-1189 (imaging)
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
Pipeline · 2 trials · 2 upcoming
| Readout | Phase | Drug | Indication | Enroll | Status |
|---|---|---|---|---|---|
| 2027-12 Estimated 50% readout ~2027-12-31 | Phase 1 | [225Ac]Ac-AKY-1189 (therapeutic), [64Cu]Cu-AKY-1189 (imaging) | Urothelial Carcinoma Bladder, Triple Negative Breast Cancer (TNBC), Hormone Receptor Positive Breast Adenocarcinoma, Non Small Cell Lung Cancer, Cervical Adenocarcinoma, Colorectal Adenocarcinoma, Head and Neck Cancer | — | recruiting |
| 2027-12 Estimated 50% readout ~2027-12-31 | Phase 1 | [225Ac]Ac-AKY-2519 (therapeutic), [64Cu]Cu-AKY-2519 (imaging) | Castration Resistant Metastatic Prostate Cancer, Prostate Cancer, mCRPC (Metastatic Castration-resistant Prostate Cancer), mCRPC, B7H3 | — | recruiting |
Catalyst news & presentations · 1
- 2026-08-13earningsEarningsEarnings releaseyahoo
Approved drugs (0)
- none — clinical-stage
Capital structure — dilution & financing
🔒 Top holders — Pro
Institutional ownership + quarter-over-quarter accumulation/trimming.
Upgrade to ProWall St ratings
strong buy · target $34 (+44% upside) · 6 analysts
- 2026-07-14JP MorganOverweight
- 2026-06-16Raymond JamesStrong Buy
- 2026-06-02HC Wainwright & Co.Buy
- 2026-04-29William BlairOutperform
- 2026-03-31HC Wainwright & Co.Buy
- 2026-03-09HC Wainwright & Co.Buy
Competitors — Urothelial Carcinoma Bladder
Recent news
- 2026-07-22Aktis Oncology Inc : Leerink Partners Assumes - Moomoo
- 2026-07-22Form 4 Aktis Oncology Inc For: 21 July By Investing.com - Investing.com Nigeria
- 2026-07-22Aktis Oncology director Ken Herrmann sells $119,274 in stock - Investing.com
- 2026-07-22Aktis Oncology director Ken Herrmann disposes of common shares worth $119,256.78 - Bitget
- 2026-07-21Aktis Oncology Insider Makes Notable Move With Fresh Stock Sale - TipRanks
- 2026-07-21Aktis Oncology director Ken Herrmann disposes of 3,065 common shares worth $77,279.54 - Bitget
- 2026-07-20Aktis Oncology, Inc. (AKTS) director sells 3,065 post-exercise - Stock Titan
- 2026-07-20Akoustis Technologies (AKTS) insider plans 4,856-share stock sale after option exercise - Stock Titan
Not financial advice. Data: ClinicalTrials.gov, SEC EDGAR, FINRA, Nasdaq, Yahoo.